Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of VHX-896 in Healthy Volunteers
NCT06803290Phase 1Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milsaperidone in schizophrenia and bipolar I disorder (2 arms), sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Comparative bioavailability of VHX-tablets under fed versus fasted conditions at 96 Hours. Started Jun 2022; status: completed.
02
Drugs
milsaperidone
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT06803290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06803290.